ReviewExperimental neurology2013
Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Review in Experimental neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Molecular Signature in Focal Cortical Dysplasia: A Systematic Review of RNA and Protein Data.International journal of molecular sciences · 2025Pooled it
- Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE): genetics, mechanisms and precision therapy.Acta neuropathologica · 2026Review
- Unraveling the Interplay Between Metabolism and Neurodevelopment in Health and Disease.CNS neuroscience & therapeutics · 2025Review
- Brain Morphometric Alterations in Focal to Bilateral Tonic-Clonic Seizures in Epilepsy Associated With Excitatory/Inhibitory Imbalance.CNS neuroscience & therapeutics · 2024Article
- Analysis of the action mechanisms and targets of herbal anticonvulsants highlights opportunities for therapeutic engagement with refractory epilepsy.Journal of molecular medicine (Berlin, Germany) · 2024Review
- The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex.Biomedicines · 2023Review
- Altered functional connectivity and network excitability in a model of cortical dysplasia.Scientific reports · 2023Article
- Pathogenesis and Therapeutic Targets of Focal Cortical Dysplasia Based on Bioinformatics Analysis.Neurochemical research · 2022Article
- The epileptogenic zone in children with tuberous sclerosis complex is characterized by prominent features of focal cortical dysplasia.Epilepsia open · 2021Article
- Ectopic HCN4 expression drives mTOR-dependent epilepsy in mice.Science translational medicine · 2020Article
- Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations.Science translational medicine · 2020Article
- How to Find Candidate Drug-targets for Antiepileptogenic Therapy?Current neuropharmacology · 2020Review
- Dendrite growth and the effect of ectopic Rheb expression on cortical neurons.Neuroscience letters · 2018Article
- Article
- Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.American journal of medical genetics. Part C, Seminars in medical genetics · 2016Review
- Dysregulation of the (immuno)proteasome pathway in malformations of cortical development.Journal of neuroinflammation · 2016Article
- Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism.JAMA neurology · 2016Article
- Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement.Nature communications · 2016Article
- Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression.Journal of neurodevelopmental disorders · 2016Article
- Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.Nature communications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Focal cortical dysplasia (FCD) and other localized malformations of cortical development represent common causes of intractable pediatric epilepsy. Insights into the cellular and molecular pathogenesis of focal cortical malformations may reveal information about associated mechanisms of epileptogenesis and suggest new therapies for seizures caused by these developmental lesions. In animal models and human studies of FCD and the related disease of Tuberous Sclerosis Complex (TSC), the mammalian target of rapamycin (mTOR) pathway has been implicated in mediating cellular and molecular changes leading to the formation of the cortical malformations and the expression of epilepsy. The use of mTOR inhibitors may represent a rational therapeutic strategy for treating or even preventing epilepsy due to FCD and TSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.